Tenderwize
Retour à la recherche

Medicinal product with active ingredient combination Oxycodone and Naloxone (ATC: N02AA55)

AOK Sachsen - Anhalt·Magdeburg, Germany·Deadline Mar 30, 2028 · 580 days left·Open·Supplies
Titre original de l'avis

Germany – Pharmaceutical products – Arzneimittel mit der Wirkstoffkombination Oxycodon und Naloxon (ATC: N02AA55)

25/100

Score d'opportunité

Needs reviewLow complexity
SuppliesOpen
Pourquoi ce score ?

Opportunité

25 / 100

Complexité

10 / 100

Facteurs de risque

The notice explicitly states it is not a public procurement, so bidders do not have the usual legal protections (e.g...

No estimated volume or value provided; actual discounts and demand are unknown. The contract may yield minimal commerci...

Analyse approfondie du portefeuille

Analyse approfondie de l'adéquation entreprise

Utilise:

  • Description
  • Industries & Services
  • Capabilities
  • Market & Experience
  • Certifications

Aperçu

Moderate opportunity

Faits clés

  • Supplies contract
  • 1 lot
  • Duration 2 YEAR
  • Supply of medicinal products containing oxycodone and naloxone (ATC: N02AA55) under non-exclusive discount agreements.
  • Open-house model: any eligible pharmaceutical company can join at any time without competitive procedure.
Afficher le résumé complet

This is an open-house model for non-exclusive discount agreements (Rabattverträge) under § 130a Abs. 8 SGB V for fixed-dose combination medicinal products containing oxycodone and naloxone (ATC: N02AA55). The buyer, AOK Sachsen-Anhalt, invites any eligible pharmaceutical company to join at any time on identical terms. The contract runs maximum 24 months starting from 01.05.2026 to 30.04.2028. The notice explicitly states it is not a public procurement under EU law and uses an 'open procedure' form only for publication. No estimated value, award criteria, or detailed eligibility criteria are provided. Participation documents must be requested from the buyer.

Risques

The notice explicitly states it is not a public procurement, so bidders do not have the usual legal protections (e.g...

No estimated volume or value provided; actual discounts and demand are unknown. The contract may yield minimal commerci...

L'analyse peut être incomplète

Seule une partie des documents de consultation a été analysée. Des exigences, certificats ou documents de soumission supplémentaires peuvent exister dans les documents restants.

Exigences clés

Eligibility

  • Must be a pharmaceutical company or consortium of pharmaceutical companies eligible under § 130a Abs. 8 SGB V.

Administrative

  • Must request participation documents from the buyer and submit them fully completed and signed.
  • Contract sign-off via electronic submission with qualified electronic signature or postal mail.

Acheteur

Localisation

Magdeburg, DEU

Profil acheteur

Ouvrir le profil

Identifiant

DE258393558

Activité

Health

Lots (1)

LOT-0001

Medicinal product with active ingredient combination Oxycodone and Naloxone (ATC: N02AA55)

Non-exclusive discount agreements for finished medicinal products with oxycodone/naloxone combination (ATC: N02AA55). Participation open at any time; no exclusivity. Contract duration max 24 months, earliest start 01.05.2026, end 30.04.2028. If the buyer later tenders exclusive contracts, open-house agreements will be terminated accordingly.

SuppliesEU fundedElectronic submission

Localisation

DEE03, Germany

Durée

2 YEAR

Catégorie

Pharmaceutical products

Date limite

Deadline Mar 30, 2028

Détails de la procédure

Date de publication
01 Mar 2026
Langues
German

Métadonnées de référence

Base juridique
32014L0024

Identifiants de référence

ID de l'appel d'offres
144037-2026

Documents (1)

Appels d'offres similaires